4.5 Article

Venovenous extracorporeal membrane oxygenation in patients with acute covid-19 associated respiratory failure: comparative effectiveness study

Journal

BMJ-BRITISH MEDICAL JOURNAL
Volume 377, Issue -, Pages -

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/bmj-2021-068723

Keywords

-

Funding

  1. University of Queensland
  2. Wesley Medical Research
  3. Prince Charles Hospital Foundation
  4. Queensland Department of Health
  5. Health Research Board of Ireland
  6. Biomedicine international training research programme for excellent clinician-scientists
  7. European Union
  8. Extracorporeal Life Support Organization
  9. International ECMO Network
  10. la Caixa Foundation
  11. Fisher and Paykel Healthcare

Ask authors/readers for more resources

An observational study found that extracorporeal membrane oxygenation (ECMO) is associated with a reduced risk of mortality in adults with COVID-19 associated respiratory failure. Age, severity of hypoxaemia, and duration and intensity of mechanical ventilation were identified as modifiers of treatment effectiveness, and should be taken into consideration when deciding to initiate ECMO in patients with COVID-19.
OBJECTIVE To estimate the effect of extracorporeal membrane oxygenation (ECMO) compared with conventional mechanical ventilation on outcomes of patients with covid-19 associated respiratory failure. DESIGN Observational study. SETTING 30 countries across five continents, 3 January 2020 to 29 August 2021. PARTICIPANTS 7345 adults admitted to the intensive care unit with clinically suspected or laboratory confirmed SARSCoV-2 infection. INTERVENTIONS ECMO in patients with a partial pressure of arterial oxygen to fraction of inspired oxygen (PaO2/FiO(2) ratio <80 mm Hg compared with conventional mechanical ventilation without ECMO. MAIN OUTCOME MEASURE The primary outcome was hospital mortality within 60 days of admission to the intensive care unit. Adherence adjusted estimates were calculated using marginal structural models with inverse probability weighting, accounting for competing events and for baseline and time varying confounding. RESULTS 844 of 7345 eligible patients (11.5%) received ECMO at any time point during follow-up. Adherence adjusted mortality was 26.0% (95% confidence interval 24.5% to 27.5%) for a treatment strategy that included ECMO if the PaO2 /FiO(2) ratio decreased <80 mm Hg compared with 33.2% (31.8% to 34.6%) had patients received conventional treatment without ECMO (risk difference -7.1%, 95% confidence interval -8.2% to -6.1%; risk ratio 0.78, 95% confidence interval 0.75 to 0.82). In secondary analyses, ECMO was most effective in patients aged <65 years and with a PaO2/FiO(2) <80 mm Hg or with driving pressures >15 cmH(2)O during the first 10 days of mechanical ventilation. CONCLUSIONS ECMO was associated with a reduction in mortality in selected adults with covid-19 associated respiratory failure. Age, severity of hypoxaemia, and duration and intensity of mechanical ventilation were found to be modifiers of treatment effectiveness and should be considered when deciding to initiate ECMO in patients with covid-19.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available